Source: International Congress 2019 – Novel findings from asthma clinical trials
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Bruns (Boston, United States of America), M. Fitzgerald (Boston, United States of America), K. Pardali (Gotherburg, Sweden), G. Philip (Gotherburg, Sweden), K. David (Gotherburg, Sweden), A. Lena (Gotherburg, Sweden), J. Fanyi (Gotherburg, Sweden), L. Jason (Melbourne, Australia), C. David (Cambridge, United Kingdom). Phase 1 evaluation of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, a potent and selective blocker of IL-4Ra. 5336

Member's Comments

No comment yet.

Related content which might interest you: In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonist Source: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007 The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan Source: Annual Congress 2010 - Airway smooth muscle cells Year: 2010 A dual-acting muscarinic antagonist, ß2-agonist [MABA] molecule (GSK961081) improves lung function in COPD. A randomised trial Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012 Efficacy of sitaxsentan, an endothelin-A receptor antagonist in PAH in traditional vs. expanded study populations Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004 Preclinical safety profile of oral SCH 527123, a novel antagonist of CXCR2 Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology II Year: 2007 IDL-2965: A Selective, highly-potent, oral Integrin antagonist for IPF Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407 Source: Eur Respir J 2007; 30: Suppl. 51, 26s Year: 2007 Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004 The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 Tachykinin 1 receptor antagonist FK888 suppresses angiotensin converting enzyme inhibitors (ACEIs)-induced tracheal inflammation, an experimental study Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Safety and efficacy of SCH527123, a novel CXCR2 antagonist, in patients with COPD Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010 Carmoterol, a new long-acting β2-agonist, positively interacts with M3-muscarinic antagonist Source: Eur Respir J 2005; 26: Suppl. 49, 215s Year: 2005 AZD3199: A potent and selective β2-adrenergic receptor agonist with rapid onset of action Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011 The novel dual D2 dopamine receptor, β2-adrenoceptor agonist Viozan™ (AR-C68397AA) is well tolerated in a dog model Source: Eur Respir J 2001; 18: Suppl. 33, 406s Year: 2001 Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011 Mas receptor antagonist inhibits the pro-resolutive effects of Angiotensin-(1-7) in an experimental model of asthma. Source: International Congress 2019 – Modelling and monitoring of airway diseases Year: 2019 Anti-asthmatic effects of losartan, a blocker of angiotensin II type 1 receptor, in a rat model of allergic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009 No interaction of roflumilast, a new, orally active, selective PDE4 inhibitor, with inhaled salbutamol Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 AZD1402/PRS-060, an inhaled Anticalin® IL-4Ra antagonist, potently inhibits IL-4 induced functional effects in human whole blood, which can be employed translationally in clinical studies. Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018